Increased circulating troponin T concentration

MedGen UID:: 1634809
•Concept ID:: C4703661
•: Finding

Synonym:	Increased troponin T level in blood

HPO:	HP:0410174

Definition

An increased concentration of tropnin T in the blood, which is a cardiac regulatory protein that controls the calcium mediated interaction between actin and myosin. Raised cardiac troponin concentrations are now accepted as the standard biochemical marker for the diagnosis of myocardial infarction. [from HPO]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVIncreased circulating troponin T concentration

Disease
- Disorder by Site
  - Disorder of cardiovascular system
    - Abnormality of the cardiovascular system
      - Abnormal cardiac test
        Abnormal cardiac biomarker test
        Increased circulating troponin T concentration

Professional guidelines

PubMed

Assessment of Risk for Interference by Circulating Biotin in Samples Received for High Sensitivity Troponin-T, Thyrotropin, and for Prostate Specific Antigen Testing by Immunoassays.

Nguyen KQN, Langevin R, Fankhauser K, Hashim IA
Clin Lab 2020 Jan 1;66(1) doi: 10.7754/Clin.Lab.2019.190642. PMID: 32013345

See all (1)

Recent clinical studies

Etiology

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.

Januzzi JL, Mohebi R, Liu Y, Sattar N, Heerspink HJL, Tefera E, Vaduganathan M, Butler J, Yavin Y, Li J, Pollock CA, Perkovic V, Neal B, Hansen MK
Circulation 2023 Aug 22;148(8):651-660. Epub 2023 Aug 21 doi: 10.1161/CIRCULATIONAHA.123.065251. PMID: 37603600

Sex Differences in Cardiac Troponin Trajectories Over the Life Course.

de Bakker M, Anand A, Shipley M, Fujisawa T, Shah ASV, Kardys I, Boersma E, Brunner EJ, Mills NL, Kimenai DM
Circulation 2023 Jun 13;147(24):1798-1808. Epub 2023 Apr 28 doi: 10.1161/CIRCULATIONAHA.123.064386. PMID: 37114498 Free PMC Article

Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T.

du Fay de Lavallaz J, Prepoudis A, Wendebourg MJ, Kesenheimer E, Kyburz D, Daikeler T, Haaf P, Wanschitz J, Löscher WN, Schreiner B, Katan M, Jung HH, Maurer B, Hammerer-Lercher A, Mayr A, Gualandro DM, Acket A, Puelacher C, Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Glarner N, Shrestha S, Manka R, Gawinecka J, Piscuoglio S, Gallon J, Wiedemann S, Sinnreich M, Mueller C; BASEL XII Investigators
Circulation 2022 Jun 14;145(24):1764-1779. Epub 2022 Apr 7 doi: 10.1161/CIRCULATIONAHA.121.058489. PMID: 35389756 Free PMC Article

Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.

Vaduganathan M, Sattar N, Xu J, Butler J, Mahaffey KW, Neal B, Shaw W, Rosenthal N, Pfeifer M, Hansen MK, Januzzi JL Jr
J Am Coll Cardiol 2022 Feb 8;79(5):432-444. doi: 10.1016/j.jacc.2021.11.027. PMID: 35115099 Free PMC Article

Exercise-Induced Cardiac Troponin I Increase and Incident Mortality and Cardiovascular Events.

Aengevaeren VL, Hopman MTE, Thompson PD, Bakker EA, George KP, Thijssen DHJ, Eijsvogels TMH
Circulation 2019 Sep 9;140(10):804-814. Epub 2019 Aug 12 doi: 10.1161/CIRCULATIONAHA.119.041627. PMID: 31401842

See all (80)

Diagnosis

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.

Sex Differences in Cardiac Troponin Trajectories Over the Life Course.

Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.

Myocardial Injury and the Release of Troponins I and T in the Blood of Patients.

Katrukha IA, Katrukha AG
Clin Chem 2021 Jan 8;67(1):124-130. doi: 10.1093/clinchem/hvaa281. PMID: 33418589

How is cardiac troponin released from injured myocardium?

Mair J, Lindahl B, Hammarsten O, Müller C, Giannitsis E, Huber K, Möckel M, Plebani M, Thygesen K, Jaffe AS
Eur Heart J Acute Cardiovasc Care 2018 Sep;7(6):553-560. Epub 2017 Dec 27 doi: 10.1177/2048872617748553. PMID: 29278915

See all (88)

Therapy

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.

Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.

Myhre PL, Liu Y, Kulac IJ, Claggett BL, Prescott MF, Felker GM, Butler J, Piña IL, Rouleau JL, Zile MR, McMurray JJV, Ward JH, Solomon SD, Januzzi JL
Eur J Heart Fail 2023 Aug;25(8):1396-1405. Epub 2023 Jul 11 doi: 10.1002/ejhf.2957. PMID: 37401523

Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO-HF trial.

Bayes-Genis A, Lupón J, Revuelta-Lopez E, Llibre C, Gastelurrutia P, Domingo M, Cediel G, Codina P, Santiago-Vacas E, Rangel-Sousa D, Fernández-Cisnal A, Miñana G, Mollar A, Núñez J
Eur J Heart Fail 2023 Aug;25(8):1439-1443. Epub 2023 Jun 27 doi: 10.1002/ejhf.2932. PMID: 37323111

Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.

Exercise training and high-sensitivity cardiac troponin T in patients with heart failure with reduced ejection fraction.

Koppen E, Omland T, Larsen AI, Karlsen T, Linke A, Prescott E, Halle M, Dalen H, Delagardelle C, Hole T, van Craenenbroeck EM, Beckers P, Ellingsen Ø, Feiereisen P, Valborgland T, Videm V; SMARTEX-HF Study Group
ESC Heart Fail 2021 Jun;8(3):2183-2192. Epub 2021 Mar 23 doi: 10.1002/ehf2.13310. PMID: 33754453 Free PMC Article

See all (39)